首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia
Institution:1. Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan;2. Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan;1. Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA;2. Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Biotechnology Center, San Diego, CA 92121, USA;1. Discovery Chemistry, Merck Research Laboratories, West Point, PA 19486, United States;2. Neuroscience, Merck Research Laboratories, West Point, PA 19486, United States;3. Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, United States;4. In Vivo Pharmacology, Merck Research Laboratories, West Point, PA 19486, United States;5. In Vitro Pharmacology, Merck Research Laboratories, West Point, PA 19486, United States;1. Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA;2. Department of Pharmacology, Merck Research Laboratories, West Point, PA 19486, USA;3. Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA;4. Department of Neuroscience, Merck Research Laboratories, West Point, PA 19486, USA
Abstract:Here, we present the design, synthesis, and SAR of dual orexin 1 and 2 receptor antagonists, which were optimized by balancing the antagonistic activity for orexin receptors and lipophilicity. Based on the prototype compound 1, ring construction and the insertion of an additional heteroatom into the resulting ring led to the discovery of orexin 1 and 2 receptor antagonists, which were 3-benzoyl-1,3-oxazinane derivatives. Within these derivatives, (?)-3h enabled a high dual orexin receptor antagonistic activity and a low lipophilicity. Compound (?)-3h exhibited potent sleep-promoting effects at a po dose of 1 mg/kg in a rat polysomnogram study, and optimal PK properties with a rapid Tmax and short half-lives in rats and dogs were observed, indicating a predicted human half-life of 0.9–2.0 h. Thus, (?)-3h (ORN0829; investigation code name, TS-142) was selected as a viable candidate and is currently in clinical development for the treatment of insomnia.
Keywords:Dual orexin receptor antagonist  DORA  Insomnia  orexin 1 receptor  orexin 2 receptor  DORA"}  {"#name":"keyword"  "$":{"id":"k0045"}  "$$":[{"#name":"text"  "_":"dual orexin receptor antagonist  SORA"}  {"#name":"keyword"  "$":{"id":"k0055"}  "$$":[{"#name":"text"  "_":"selective orexin receptor antagonist  PSG"}  {"#name":"keyword"  "$":{"id":"k0065"}  "$$":[{"#name":"text"  "_":"polysomnography  SAR"}  {"#name":"keyword"  "$":{"id":"k0075"}  "$$":[{"#name":"text"  "_":"structure-activity relationship  Cbz"}  {"#name":"keyword"  "$":{"id":"k0085"}  "$$":[{"#name":"text"  "_":"benzyloxycarbonyl  Boc"}  {"#name":"keyword"  "$":{"id":"k0095"}  "$$":[{"#name":"text"  "$$":[{"#name":"italic"  "_":"tert"}  {"#name":"__text__"  "_":"-butoxycarbonyl  Ms"}  {"#name":"keyword"  "$":{"id":"k0105"}  "$$":[{"#name":"text"  "_":"methanesulfonyl  IBX"}  {"#name":"keyword"  "$":{"id":"k0115"}  "$$":[{"#name":"text"  "_":"2-iodoxybenzoic acid  T3P®"}  {"#name":"keyword"  "$":{"id":"k0125"}  "$$":[{"#name":"text"  "_":"propylphosphonic acid anhydride  DIPEA"}  {"#name":"keyword"  "$":{"id":"k0135"}  "$$":[{"#name":"text"  "$$":[{"#name":"italic"  "_":"N"}  {"#name":"__text__"  "_":"  "}  {"#name":"italic"  "_":"N"}  {"#name":"__text__"  "_":"-diisopropylethylamine  CDI"}  {"#name":"keyword"  "$":{"id":"k0145"}  "$$":[{"#name":"text"  "_":"1  1′-carbonyldiimidazole  PPL"}  {"#name":"keyword"  "$":{"id":"k0155"}  "$$":[{"#name":"text"  "_":"lipase from Porcine Pancreas  MTBE"}  {"#name":"keyword"  "$":{"id":"k0165"}  "$$":[{"#name":"text"  "$$":[{"#name":"__text__"  "_":"methyl "}  {"#name":"italic"  "_":"tert"}  {"#name":"__text__"  "_":"-butyl ether  REMD"}  {"#name":"keyword"  "$":{"id":"k0175"}  "$$":[{"#name":"text"  "_":"replica-exchange molecular dynamics  CYP"}  {"#name":"keyword"  "$":{"id":"k0185"}  "$$":[{"#name":"text"  "_":"cytochrome P450  CHO"}  {"#name":"keyword"  "$":{"id":"k0195"}  "$$":[{"#name":"text"  "_":"Chinese hamster ovary  ER"}  {"#name":"keyword"  "$":{"id":"k0205"}  "$$":[{"#name":"text"  "_":"efflux ratio  P-gp"}  {"#name":"keyword"  "$":{"id":"k0215"}  "$$":[{"#name":"text"  "_":"P-glycoprotein  RHS"}  {"#name":"keyword"  "$":{"id":"k0225"}  "$$":[{"#name":"text"  "_":"right hand side  PPB"}  {"#name":"keyword"  "$":{"id":"k0235"}  "$$":[{"#name":"text"  "_":"plasma protein binding  CSF"}  {"#name":"keyword"  "$":{"id":"k0245"}  "$$":[{"#name":"text"  "_":"cerebrospinal fluid  MED"}  {"#name":"keyword"  "$":{"id":"k0255"}  "$$":[{"#name":"text"  "_":"minimum effective dose
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号